Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Relapsing-remitting Multiple Sclerosis (rrMS) Clinical Trial

Official title:
Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)

Status Completed

Clinical Trial Summary

To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the Imaging Protocol of GEH120714 (18F) Injection. Study recruits healthy volunteers and participants with relapsing and remitting multiple sclerosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Relapsing-remitting Multiple Sclerosis (rrMS)
Sclerosis

Clinical Trial Details

NCT number	NCT01738347
Study type	Interventional
Source	GE Healthcare
Contact
Status	Completed
Phase	Phase 1
Start date	April 2013
Completion date	May 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05177523` - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Withdrawn	`NCT05172466` - Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab	N/A
Completed	`NCT05304520` - A Study for Tysabri Participant Preference
Completed	`NCT04115488` - Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®	Phase 3
Recruiting	`NCT06430671` - Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis	Phase 1/Phase 2
Recruiting	`NCT05811416` - A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Active, not recruiting	`NCT03846219` - MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)	Phase 2
Completed	`NCT02587065` - Plegridy Satisfaction Study in Participants	Phase 4
Not yet recruiting	`NCT02568111` - Brimonidine Tartrate for the Treatment of Injection Related Erythema	Phase 4
Terminated	`NCT01633112` - MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone	Phase 3
Terminated	`NCT02881567` - Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab	Phase 3
Not yet recruiting	`NCT05245344` - Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study